CUSIP: 928251107
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
1,113,021
-
Share change
-
-451,336
-
Total reported value
-
$873,775
-
Price per share
-
$0.78
-
Number of holders
-
16
-
Value change
-
-$346,045
-
Number of buys
-
3
-
Number of sells
-
9
Quarterly Holders Quick Answers
What is CUSIP 928251107?
CUSIP 928251107 identifies VRPX - VIRPAX PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 928251107:
Institutional Holders of VIRPAX PHARMACEUTICALS INC - COM (VRPX) as of Q1 2023
As of 31 Mar 2023,
VIRPAX PHARMACEUTICALS INC - COM (VRPX) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,113,021 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, PNC Financial Services Group, Inc., RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, Belpointe Asset Management LLC, Warberg Asset Management LLC, Cambridge Investment Research Advisors, Inc., NORTHERN TRUST CORP, and Quantum Private Wealth, LLC.
This page lists
16
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.